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Abstract: Acyclic nucleoside phosphonates are of medical relevance and deserve detailed 
chemical characterization. We focus here on (S)-9-[3-hydroxy-2-
(phosphonomethoxy)propyl]adenine (HPMPA) and include for comparison 9-[2-
(phosphonomethoxy)ethyl]adenine (PMEA), as well as the nucleobase-free 
(phosphonomethoxy)ethane (PME) and (R)-hydroxy-2-(phosphonomethoxy)propane (HPMP). 
The acidity constants of H3(HPMPA)+ were determined and compared with those of the related 
phosph(on)ate derivatives; they are also needed to understand the properties of the metal ion 
complexes. Given that in vivo nucleotides and their analogues participate in reactions typically as 
divalent metal ion (M2+) complexes, the stability constants of the M(H;HPMPA)+ and 
M(HPMPA) species with M2+ = Mg2+, Ca2+, Sr2+, Ba2+, Mn2+, Co2+, Ni2+, Cu2+, Zn2+, and Cd2+ 
were measured. Comparisons between the results for HPMPA2– and the previous data for 
PMEA2–, HPMP2– and PME2– revealed that for most M(HPMPA) complexes the enhanced 
stability (the enhancement relative to the stability of a simple phosphonate-M2+ coordination), 
can solely be explained by the formation of 5-membered chelates involving the ether oxygen. 
These chelates occur in equilibrium with simple 'open' phosphonate-M2+ species, the 
phosphonate group being the primary binding site. The only exceptions are the M(HPMPA) 
complexes of Ni2+, Cu2+, and Zn2+, which show an additional stability enhancement; in these 
instances not only the indicated 5-membered chelates are formed, but M2+ coordinates in 
addition to N3 of the adenine residue forming a 7-membered chelate ring. This observation 
regarding N3 is important because it emphasizes the metal ion affinity of this site (which is often 
ignored). Note that in the DNA double helix N3 is exposed to the solvent in the minor groove. 
The stability data for the monoprotonated M(H;HPMPA)+ complexes suggest that these carry H+ 
at the phosphonate group whereas M2+ is partly at the nucleobase and partly also at the 
phosphonate group. The ratios of these isomers depend on the metal ion involved, e.g., for 
Cu(H;HPMPA) the ratio of the isomers is about 1:1. 
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1. Introduction 
 
Acyclic nucleoside phosphonates (ANPs) and their derivatives are a highly successful class of 
antiviral compounds.[1,2] The first ANP to be synthesized and evaluated for its antiviral activity 
was (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine [(S)-HPMPA] in 1986.[3] This 
compound is derived from the acyclic adenosine analogue [(S)-9-(2,3-
dihydroxypropyl)adenine],[4] which has been commercialized in the Czech Republic as 
Duviragel against Herpes simplex virus.  
Although (S)-HPMPA showed impressive activities against a range of DNA viruses,[3] it 
was never commercialized as a drug. However, it spawned three immensely successful drug 
molecules, namely (S)-9-[3-hydroxy-2-phosphonomethoxy)propyl]cytosine [(S)-HPMPC; 
Cidofovir]; 9-[2-(phosphonomethoxy)ethyl]adenine) (PMEA; Adefovir), and (R)-9-[2-
(phosphonomethoxy)propyl]adenine) [(R)-PMPA; Tenofovir].[1,2] HPMPC differs from HPMPA 
by replacement of the nucleobase, PMEA lacks a hydroxymethyl group, and PMPA lacks the 3-
hydroxyl group present in HPMPA (Figure 1, vide infra). With a similar broadband antiviral 
spectrum as HPMPA, Cidofovir (HPMPC) attained FDA (1996) and EMA (1997) approval, 
under the tradename Vistide, for the treatment of human cytomegalovirus retinitis in AIDS 
patients.[5] Cidofovir (now generic) remains in use for a variety of viral infections.[1] 
Furthermore, the oral prodrug Brincidofovir, the hexadecyloxypropyl ester of HPMPC has been 
given orphan designation for treatment of smallpox.[6] Since 2003, Adefovir (PMEA) is in use in 
the form of its orally available bis(pivaloyloxymethyl) ester, Adefovir dipivoxil (Hepsera), for 
the treatment of hepatitis B virus infections.[7] Tenofovir (PMPA) is available since 2002 as an 
oral prodrug, Tenofovir disoproxil fumarate (TDF, Viread), against infections with HIV-1.[8] 
TDF is a component of several combination regimens, including Truvada which can prevent 
HIV-1 infections.[9]  
(S)-HPMPA does not only display antiviral activity, but has also been considered for the 
treatment of Schistosomiasis that is caused by a flatworm,[10] Malaria caused by the unicellular 
parasite Plasmodium falciparum,[11] and for combating infections with the protozoon 
Trypanosoma brucei which causes sleeping sickness.[12] In addition, it exhibits 
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immunobiological activity, leading to the activation of macrophages.[13] It also remains in the 
focus of antiviral research; in particular, a range of oral prodrugs have been investigated,[14-17] 
most recently with a view to combat adenovirus infections that are otherwise difficult to 
tackle.[18,19] 
insert Figure 1 close to here 
The mechanistic details for the activity of ANPs against viruses are relatively well 
studied.[20] ANPs are essentially isosteric analogues of the respective (2'-deoxy)nucleoside 5'-
monophosphates (5'-NMPs) such as 5'-(d)AMP2– (Figure 1).[21–27] Owing to their fairly polar 
character and charge(s) on the phosphonate group, unmodified ANPs need to be administered by 
injection, and are thought to be taken up into cells by endocytosis,[28] whereas the esterified oral 
prodrugs may permeate through cell membranes,[20] and are then de-esterified by phospholipase 
C or phosphodiesterase.[20] Free phosphonates are successively phosphorylated by cellular 
kinases; action of AMP/dAMP kinase on HPMPA yields its diphosphorylated derivative  
HPMPApp4–.[29,30] Such (2'-deoxy)nucleoside 5'-triphosphate [(d)NTP4–] analogues serve as 
alternative substrates and effective competitive inhibitors of nucleic acid polymerases.[30] In 
addition, strands harbouring a single HPMP derivative are inefficient templates for further 
nucleic acid synthesis.[31] Summarily, these actions inhibit the replication of the viral genome 
and hence virus proliferation. 
The phosphonate group is a cornerstone for the clinical success of the ANPs.[32] It 
circumvents the requirement for a nucleoside kinase, and in contrast to a hydrolysable phosphate 
ester group, it avoids degradation and inactivation by phosphatases and esterases.[33] Moreover, 
after incorporation of the ANP into the growing nucleic acid strand, it also prevents the excision  
of the ANP by proof-reading polymerases.[20]  
Since the substrates for kinases and nucleic acid polymerases are actually metal complexes 
of the respective nucleoside mono- or triphosphates,[34–37] it is conceivable that the metal ion-
binding properties of ANPs may also play a role in the activity of these compounds, motivating a 
research programme dedicated to understanding stability and structures of ANP metal 
complexes.[35,38,39] The ether oxygen has been shown to be essential for biological activity[40,41] 
but also to play a pivotal role in metal ion binding of these compounds: It permits the formation 
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of five-membered chelates.[38,42–47] Finally, in terms of biological activity, the position of the 
hydroxyl group matters, as "iso-HPMPA", (S)-9-[2-hydroxy-2-
(phosphonomethoxy)propyl]adenine), is inactive.[48]  
Summarily, the groups that are critical to the metal ion-binding properties of ANPs also 
influence the suitability of the ANPs as enzyme substrates. In the present study, we investigate 
the metal ion-binding properties of H(HPMPA)– and HPMPA2– which will allow comparisons 
with its congener PMEA species. Previously HPMPA had been used as a ligand in aqueous 
solution in two studies: Most recently the stability and structure of the ternary 
Cu(Arm)(H;HPMPA)+ and Cu(Arm)(HPMPA) complexes, where Arm = 2,2'-bipyridine or 1,10-
phenanthroline, were examined.[39] The binary H(HPMPA)– and HPMPA2– systems with Ca2+, 
Cu2+, and Zn2+ were investigated previously in a preliminary study and these results were 
confirmed now.[49] With comparative data for the nucleobase-free parent compound HPMP now 
available,[47] it has become possible to comprehensively evaluate the stability constants of the 
binary M(H;HPMPA)+ and M(HPMPA) complexes, formed with M2+ = Mg2+, Ca2+, Sr2+, Ba2+, 
Mn2+, Co2+, Ni2+, Cu2+, Zn2+, and Cd2+, and to assess their structures in solution revealing in part 
up to three different isomeric species, including N3 as a binding site.  
 
2. Results and Discussion 
 
Nucleobases, especially purines, and their derivatives can undergo self-associations via p 
stacking.[23,50–52] Therefore, the experimental conditions for the determination of the stability 
constants of the M(H;HPMPA)+ and M(HPMPA) complexes by potentiometric pH titrations in 
aqueous solution were selected such that the results refer to monomeric species (see 4. 
Experimental Section). With ligand concentrations of 0.3 mM, this is ascertained as shown 
previously for PMEA.[38] These statements[44,52] as well as the contents of Sections 2.1, 2.2, and 
2.3 are partially analogous to previous related studies.[43,44,46,52] 
 
2.1 Acidity Constants of H3(HPMPA)+ and of Related Species  
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HPMPA2–, like PMEA2–,[21] can accept three protons, two at the phosphonate group and one at 
the N1 site of the purine residue. Further protonations are possible at N7 and N3, but these 
protons are released[53] with pKa < 0 and are thus not of relevance here, though as metal ion-
binding sites they may be relevant [see Sections 2.4, 2.5 (N1, N7) and 2.6, 2.7 (N3, N7)]. At 
pH > 0, the strongest acid that exists in aqueous solution based on HPMPA2– is H3(HPMPA)+. 
The corresponding three deprotonation steps, written in a general manner, where NP2– = 
nucleoside phosph(on)ate (see Figure 1), are the following ones: 
 H3(NP)+    H2(NP)± + H+  (1a) 
 
  
= [H2(NP)±][H+]/[H3(NP)+] (1b) 
 H2(NP)±    H(NP)– + H+ (2a) 
  = [H(NP)–][H+]/[H2(NP)±] (2b) 
 H(NP)–    NP2– + H+ (3a) 
  = [NP2–][H+]/[H(NP)–] (3b) 
insert Table 1 close to here 
The acidity constants for H3(HPMPA)+ are listed in Table 1 together with related data.[53–
64] From the assembled constants the following conclusions, next to others, are possible: 
(1) The protons of H3(HPMPA)+ are released from the acidic sites in the order 
P(O)(OH)2 > (N1)H+ > (OH) (entry 3). 
(2) The given order is confirmed by entries 1 to 3 and it also holds for H3(PMEA)+ (entry 
5). 
(3) The P(O)(OH)2 group of the nucleobase-free compounds H2(HPMP) and H2(PME) is 
somewhat less acidic than the corresponding group of H3(HPMPA)+ and H3(PMEA)+ (∆ pKa ca. 
0.35). The reason is that the repulsive effect of (N1)H+ is missing. 
(4) The site attribution for H3(AMP)+ (entry 8) follows from entries 1, 6, and 7, and it is 
analogous to that of H3(HPMPA)+ and H3(PMEA)+.  
(5) The phosphate derivatives are more acidic than the phosphonate ones. This is 
 
 
KH3(NP)
H
 
 
KH2(NP)
H
 
KH(NP)
H
PO2–
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especially evident for (OH) of methyl phosphate (entry 9) and methylphosphonate (entry 
10) (∆ pKa ca. 1.15). 
(6) The consequence of point (5) is that at the physiological pH of 7.5 about 50% of 
methylphosphonate exist in its monoprotonated form, whereas for methyl phosphate this is the 
case for only about 7%. Consequently, at physiological pH there is less proton competition 
regarding metal ion binding with phosphate monoesters than there is for phosphonates.  
(7) A final point to be emphasized is that in adenine derivatives with a free N1 site, N7 
possesses a considerable basicity (column 4 of Table 1). This is of relevance for macrochelate 
formation, e.g., in M(AMP) complexes.[56,57,65–68] 
 
2.2 Stability Constants of the M(H;HPMPA)+ and M(HPMPA) Complexes 
 
The experimental data of potentiometric pH titrations (see 4. Experimental Section) allow the 
determination of the stability constants according to Equilibria (4a) and (5a), which are written 
in a general manner with NP2– = HPMPA2–. It should be noted that in formulae like M(H;NP)+, 
the H+ and NP2– are separated by a semicolon to facilitate reading, yet they appear within the 
same parenthesis to indicate that the proton is at the ligand without defining its location:[46] 
M2+ + H(NP)–  M(H;NP)+ (4a) 
 = [M(H;NP)+]/([M2+][H(NP)–]) (4b) 
M2+ + NP2–  M(NP) (5a) 
 = [M(NP)]/([M2+][NP2–]) (5b) 
For the M2+/HPMPA system, Equilibria (2a), (3a), (4a), and (5a) are sufficient to obtain an 
excellent fitting of the titration data provided that the evaluation is not carried into the pH range 
where the formation of hydroxo species occurs; this was evident from the titrations without the 
ligand (4. Experimental Section).[46] 
Naturally, Equilibria (4a) and (5a) are also connected via Equilibrium (6a): 
P(O)2–
 
 
KM(H;NP)
M
 
 
KM(NP)
M
  
8 
M(H;NP)+  M(NP) + H+ (6a) 
 = [M(NP)][H+]/[M(H;NP)+] (6b) 
The corresponding acidity constant [Eq. (6b)] may be calculated with Equation (7): 
 =  +  –  (7) 
The results are listed in Table 2. The stability constants given for the M(H;NP)+ complexes 
carry, in part, rather large error limits because the formation degree of these species was low. 
insert Table 2 close to here 
The stability constants of the M(H;HPMPA)+ complexes reflect the Irving-Williams 
sequence[69] and this might be taken as a hint that (N)–M2+-binding, that is, involvement of the 
nucleobase residue, is of some relevance.[70] 
In contrast, the stability constants of the M(HPMPA) complexes with the 3d metal ions 
confirm the long-standing experience[70] that the stabilities of phosph(on)ate-metal ion 
complexes often do not strictly follow[57,66,71,72] the Irving-Williams sequence.[69] This  
observation agrees with the fact that in ligands of this kind the phosph(on)ate group is 
generally[35,66,67,71,73,74] the main stability-determining binding site (see Figure 3, vide infra). For 
the alkaline earth ions, complex stability decreases (Table 2, column 3), as one might expect, 
with increasing ionic radii, thus indicating that M2+ binding at the phosphonate group occurs at 
least partly innersphere.  
 
2.3 Where Is the Proton in the Monoprotonated M(H;HPMPA) Species? 
 
The evaluation of potentiometric pH titration data only allows the determination of the stability 
constants of the M(H;HPMPA)+ complexes. Further information is required to detect the binding 
sites of the proton and the metal ion.[46,47,75,76]  
Regarding the location of the proton it is helpful to consider the deprotonation Equilibrium 
(6a). The corresponding acidity constant follows from Equation (7) and these results are listed in 
 
 
KM(H;NP)
H
 
pKM(H;NP)
H pKH(NP)
H
 
log KM(H;NP)
M log KM(NP)
M
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column 4 of Table 2. The values for these acidity constants, , are all in the pKa 
range of about 4.58 (± 0.22) to 5.5 (± 0.5). This means, these values are about 0.44 (± 0.22) to 
1.4 (± 0.5) pK units above the pKa value of the adenine nucleobase (  =  = 
4.14 ± 0.01; Table 1, entry 3), but below  = = 6.84 ± 0.01.  
The above observation allows to conclude that the proton in these (M;HPMPA)+ 
complexes resides at the phosphonate group, and that the presence of M2+ increases the acidity of 
the (OH) group by about 1.3 (± 0.5) to 2.26 (± 0.22) pK units.  
 
2.4 Where Is the Metal Ion Coordinated in the Monoprotonated M(H;HPMPA)+ 
Complexes? 
 
In the second to the last paragraph of Section 2.2 a hint is given for a (N)–M2+ binding, that is, 
for a M2+-adenine residue interaction, and in the preceding Section 2.3 it was concluded that in 
the monoprotonated M(H;HPMPA)+ complexes the proton is located at the phosphonate group 
of HPMPA2–. Hence, the formation of the monoprotonated M(H;HPMPA)+ complexes can occur 
in two ways: That is, M2+ coordinates at the nucleobase with the proton at the phosphonate 
group, this species being represented by the expression (H·HPMPA·M)+, or the other possibility 
is that both the proton and the metal ion are located at the phosphonate group; this species is 
written as (H·M·HPMPA)+, though one might imagine that the M2+ ion at the phosphonate 
interacts to some extent also with the adenine residue forming a macrochelate as expressed by 
(H·HPMP·M·A)+. These two species with M2+ at the phosphonate group we consider together 
under the label H(M·HPMPA)+. The existence of a further species with the metal ion at the 
phosphonate group and the proton at the N1 site is rather unlikely because in the uncomplexed 
species (H·HPMPA·H)+/– the pKa of the (N1)H+ site is 4.14 (Table 1, entry 3, column 5) and for 
(M·HPMPA·H)+ it will be similar or even lower and an isomer with such a low pKa value is 
expected not to be of a significant relevance in the context of the other isomers formed (vide 
infra Table 4, columns 5 and 6). 
At this point we are left with (H·HPMPA·M)+ and H(M·HPMPA)+, and these two 
 
pKM(H;HPMPA)
H
 
pK(N1)H
H
 
pKH2(HPMPA)
H
pKP(O)2(OH)
H pKH(HPMPA)
H
P(O)2–
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possibilities are summarized in Figure 2 where the metal ion at the adenine residue (with Ni2+ as 
an example) is given in the upper pathway. The isomers with M2+ at the phosphonate group, if 
chelated or not, are indicated as H(M·HPMPA)+.  
insert Figure 2 close to here 
Both protonated species lead after deprotonation to the same complex, M(HPMPA), which is 
shown in the equilibrium scheme of Figure 2 at the right. By determining the micro stability 
constants of the (H·HPMPA·M)+ and H(M·HPMPA)+ species one may evaluate which of the 
two pathways is the dominating one. The interrelations between the macroconstants and the 
microconstants, which appear in the scheme, are given in the lower part of Figure 2. 
From Figure 2 it follows that there are four unknown microconstants but only three 
equations which interrelate these micro- with the experimentally accessible macroconstants. 
Hence, one of the microconstants needs to be obtained in an independent manner. From the 
structures shown in Figure 1 it is evident that the adenine moiety of adenosine (Ado) is a good 
mimic of the corresponding residue of H(HPMPA)–. Certainly, the corresponding two metal ion 
complexes M(Ado)2+ and M(H;HPMPA)+ differ by a charge of one and this needs to be taken 
into account in the evaluations. 
There is also a difference in the basicity of N1 in Ado compared with that in H(HPMPA)– 
which is reflected in the corresponding acidity constants. For H2(HPMPA)+/– it holds 
 
= 4.14 ± 0.01 (Table 1) and for H(Ado)+  = 3.61 ± 0.03, a value which 
shows no marked dependence on the ionic strength between I = 0.1 and 0.5 M (Table 1).[27] The 
difference in acidity as expressed in Equation (8)  
D pKa = (4.14 ± 0.01) – (3.61 ± 0.03) = 0.53 ± 0.03 (8) 
is expected (due to the known dependence of log Kstability on pKa) to be reflected in the metal ion-
binding strength of the adenine residue. The straight-line plots of o-substituted pyridine-type 
ligands reflect metal ion binding at N1,[77] whereas the plots of 1-methyl-4-aminobenzimidazole-
type (= 9-methyl-1,3-dideazaadenine) or 1,4-dimethylbenzimidazole-type (= 6,9-dimethyl-1,3-
dideazapurine) ligands reflect the metal ion affinity of the N7 side.[78] As the dichotomy for 
metal-ion binding, especially between N1 and N7 is well known,[79] we used the average of the 
 
pKH2(HPMPA)
H pKH(Ado)
H
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slopes m of the two straight-line plots (Table 3, column 2) as the best available slope, mav, for the 
dependence of the N1,N7-metal ion affinity. As the contribution of the term mav·D pKa is small, 
no significant error is introduced by this procedure. 
If one summarizes the various terms indicated above, one obtains an estimate for the micro 
stability constant of the (H·HPMPA·M)+ isomer. This is expressed in Equation (9): 
 log 
 
+ mav · D pKa + charge effect = log  (9a) 
 log + mav · (0.53 ± 0.03) + (0.40 ± 0.15) = log  (9b) 
The charge effect results from the negative charge of the (OH) group on the metal ion 
affinity of the adenine residue. We applied a charge effect of 0.40 ± 0.15 log units with a 
relatively large error limit; its size has been repeatedly confirmed.[38,56,59,80] The corresponding 
results are summarized in Table 3.[80–82] The complexes of the alkaline earth ions are not 
considered because the stabilities of the corresponding M(H;HPMPA)+ (Table 2) and M(Ado)2+ 
(ref.[81]) species are very low and the error limits are thus large. 
insert Table 3 close to here 
The information assembled in Table 3 allows, in combination with the stability constants 
listed in Table 2, the calculation of the microconstants defined in Figure 2. The corresponding 
micro stability as well as the micro acidity constants are summarized in Table 4. The micro 
acidity constants are of special interest because one would expect that a metal ion coordinated at 
the adenine residue will enhance the acidity of a proton at the phosphonate group less than a 
metal ion that is coordinated next to the proton also at the phosphonate group. Therefore, from 
the observation that for the Mn2+, Co2+, and Cd2+ complexes it holds   > 
, it follows that in these instances the isomer with the metal ion at the nucleobase 
residue dominates. The micro acidity constants indicate further that for the complex with Zn2+ 
the reverse is true, that is, the lower pathway in Figure 2 dominates demonstrating that matters 
can be more complicated. For the Ni2+ and Cu2+ complexes the two micro acidity constants are 
rather similar indicating an approximately even formation degree of the two species with M2+ at 
the adenine residue or at the phosphonate group. Indeed, these indications are confirmed below. 
KM(Ado)
M kH·HPMPA·M
M
KM(Ado)
M kH·HPMPA·M
M
P(O)2–
 pkH⋅HPMPA⋅M
H
 
pkH(M⋅HPMPA)
H
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insert Table 4 close to here 
 
 2.5 Attempt to Determine the Formation Degrees of the M(H;HPMPA)+ Isomers 
 
Naturally, at this point one wonders about the position of the intramolecular equilibrium between 
the two isomeric species (H·HPMPA·M)+ and H(M·HPMPA)+ seen in the equilibrium scheme in 
Figure 2. This position is defined by the dimension-less intramolecular equilibrium constant KI 
which corresponds to the ratio R of these species; R is defined by Equation (10): 
 R =  =  (10) 
The two micro stability constants are interlinked with each other (see also the equilibrium 
scheme) by Equation (a) of Figure 2. Based on these equations and the information assembled in 
Tables 2 and 3 the ratio R can be calculated as well as the formation degree of the species in 
which M2+ is located at the nucleobase residue (Equation (11)): 
 % (H·HPMPA·M)+ = 100·R/(1 + R) (11) 
The corresponding results are provided in Table 5.  
insert Table 5 close to here 
Not surprisingly, the error limits of the results presented in Table 5 are large, however, it is 
still evident that both isomers occur in varying amounts. In addition, it is comforting to note that 
the interpretations given in the context of Table 4 are confirmed. Further interpretations are 
hampered by the large errors because for % (H·HPMPA·M)+ the lower limits for Mn2+, Co2+, 
and Cd2+ overlap with the upper limits of Ni2+ and Cu2+. The only value that is significantly 
different from all the others is 17±6 for % (H·HPMPA·Zn)+. The reason for this observation is 
most likely that Zn2+ has a chameleon-like coordination sphere[83] and switches easily from an 
octahedral one to a tetrahedral one, that is, from coordination number 6 (via 5) to 4.[83] However, 
overall the observation that metal ions, without the support of any other binding site, can 
 
[(H ⋅ HPMPA ⋅ M)+ ]
[H(M ⋅ HPMPA)+ ]  
kH⋅HPMPA⋅M
M
kH(M⋅HPMPA)
M
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coordinate to the adenine residue[79] (via N1 and/or N7)[84] is certainly of biological relevance. 
The same is true for the proof that H+ and M2+ may simultaneously bind to a given 
phosph(on)ate group. Regarding metal ion coordination to phosphodiester units in 
oligonucleotides this is also of relevance. 
 
2.6 Definition of the Stability Enhancements for M(NP) Complexes and Comparisons 
Among Structurally Related Species. Effects of Substituents 
 
A stability enhancement for any ANP complex is observed, if the experimentally measured 
stability constant [Eq. (5)] is larger than the one expected based on a simple phosphonate-metal 
ion coordination. For the M(PMEA) complexes stability enhancements were found. Based on 
steric and chemical considerations,[35,74] which were confirmed by NMR studies,[85] it was 
concluded that the dominating pathway involves N3 and thus the upper pathway of the 
Equilibrium Scheme (12);[45] if at all, in the case of Ni2+ (ref.[86]) or Cu2+ (ref.[87]) only very low 
amounts of M(PMEA)cl/N7 form (see also ref.[45]). For the case of Ni(HPMPA) or Cu(HPMPA) it 
is concluded that M(NP)cl/N7 is not of relevance (see also below). 
 
 
 
                               (12) 
 
 
The three equilibrium constants of the upper part of the Equilibrium Scheme (12) are defined by 
Equations (13) to (15): 
 =  (13) 
         KI/O =  (14) 
M2+ +  NP2– M(NP)
M(NP)
M(NP)
K MM(NP)op
K I/O/N3 M(NP)
K I/N7
cl/N7
op
K I/O
cl/O cl/O/N3
 
KM(NP)op
M
 
[M(NP)op]
[M2+ ][NP2− ]
 
[M(NP)cl/O]
[M(NP)op]
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     KI/O/N3 =  (15) 
With these definitions the measured overall stability constant [Eq. (5b)] can be redefined 
by Equations (16a) through (16d): 
 =  (16a) 
=  (16b) 
=  + KI/O ·  + KI/O/N3 · KI/O ·   (16c) 
= (1 + KI/O + KI/O · KI/O/N3) (16d) 
The connection between the overall intramolecular equilibrium constant KI/tot [Eq. 
(18)][35,38,74,87] and the accessible stability enhancement log DM/NP, which is self-explaining [Eq. 
(17)], is given by Equations (18a) through (18e):[43,86] 
log DM/NP = log  – log  (17a) 
= log  – log  (= log D) (17b) 
KI/tot =  – 1 = 10log D – 1 (18a) 
 =  (18b) 
 =  (18c) 
 = KI/O + KI/O/N3 · KI/O (18d) 
 = KI/O (1+ KI/O/N3) (18e) 
At this point it is instructive to consider briefly the effect of substituents at C2 and C6 on 
metal-base interactions. The shift of the amino group from C6 in PMEA to C2 in 9-[(2-
phosphonomethoxy)ethyl]-2-aminopurine (PMEA2AP)[44] relieves steric hindrance on the N7 
site, but hinders M2+ coordination at N3 (see structures in Figure 1).[44] Accordingly, in 
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complexes with 9-[2-(phosphonomethoxy)ethyl]-2-amino-6-dimethylaminopurine 
(PME2A6DMAP)[46] the N3 site is blocked by the C2(NH2) group and coordination at N7 is 
sterically hindered by the N(CH3)2 group at C6. Hence, in M(PME2A6DMAP) complexes only 
the 5-membered chelate as seen in Equilibrium (19)[45] forms; no isomers with metal ion-
nucleobase interactions occur.[46] 
 
 
 (19)  
Considering the structural relationship between PMEA and HPMPA (Figure 1) we conclude 
from the summaries given in this section that for M(HPMPA) complexes (if at all) only the 
upper pathway seen in the Equilibrium Scheme (12) is of real relevance (see Section 2.7). 
insert Figure 3 close to here 
A quantitative evaluation regarding stability enhancements [Eq. (17)] is possible as 
indicated in Figure 3. The straight reference lines are based on the relationship between 
log  and  [Eq. (20)]: 
 log  = m ·  + b (20) 
The slopes m and the intercepts b with the y axis are tabulated for all M2+ systems considered 
here.[38,66,73] The eight data points (empty circles) refer to simple phosph(on)ate systems (see 
legend of Figure 3), where R in R-PO3 does not interact with M2+ (neither in a positive nor in a 
negative manner). 
The data points for the M(NP) systems of HPMPA2–/PMEA2– and HPMP2–/PME2– (Figure 
1) are all above their reference lines proving an enhanced stability (Figure 3). Application of 
Equation (20) with the known parameters for m and b, and the value of the ligand 
considered gives the log stability constant log , i.e., of the isomer in which M2+ is only 
coordinated to the phosphonate group [Eq. (19); species at the left]. Hence, the vertical dotted 
lines in Figure 3 correspond to the log DM/NP values defined in Equation (17). Of course, the 
stability enhancements observed in Figure 3 and the values for log DM/NP [Eq. (17)] represent the 
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total enhancement which involves all possible isomers. In Table 6 the results are assembled for 
the M(HPMPA) systems. Any breakdown into individual isomers has to occur in separate steps 
based on further arguments. 
insert Table 6 close to here 
 
2.7 Evaluation of the Stability Enhancements of the M(HPMPA) Complexes 
 
From the stability enhancements seen in Figure 3 which correspond to the log DM/HPMPA values 
[Eq. (17)] listed in Table 6 (column 4) it follows that next to the phosphonate group, at least in 
part other binding sites of HPMPA2– (see Figure 1) allowing chelate formation, must be 
involved. The total amount of closed species is given by Equation (21),  
 % M(NP)cl/tot = 100 · KI/tot / (1 + KI/tot) (21) 
 and the percentage of the open species (op) equals of course: 
 % M(NP)op = 100 % – % M(NP)cl/tot (22) 
The potential metal ion-binding sites of HPMPA2– are the ether-oxygen of the –CH2–O–CH2–PO  
residue, the hydroxyl group of the HO–CH2– side chain and the N3 or N7 sites of the adenine 
moiety, the N7 site not being of relevance, as discussed. Furthermore, the N1 site cannot be reached 
by a metal ion coordinated at the phosphonate group.[35,38,85] To solve this rather complex problem 
we employ comparisons with the nucleobase-free HPMP2– and with the side-chain-free PMEA2–. 
To this end we list in Table 7 the corresponding log DM/NP values.  
insert Table 7 close to here 
From the differences D log DHPMPA–HPMP follows directly the effect of the adenine residue 
on the stability of the complexes. It is apparent that this residue inhibits complexation of Ba2+, 
Sr2+, Ca2+, Mg2+ and Mn2+. Interestingly, the log DM/HPMPA values (column 2) correspond for the 
mentioned metal ions to those of log DM/PMEA (column 5). Furthermore, it has been concluded 
that for the complexes of Ba2+, Sr2+, and Ca2+ a significant portion of tridentate binding of the 
 3
2–
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HPMP2– ligand occurs; that is, formation degrees of about 30 % of the M(HPMP)cl/O/OH isomers 
are reached.[47] Evidently, with HPMPA2– such a type of chelate formation does not occur; most 
likely, the adenine residue hampers, due to its steric bulk, the formation of a species analogous to 
M(HPMP)cl/O/OH. In contrast, from the differences listed in column 4 of Table 7 for the 
complexes with Ni2+ and Cu2+ it follows unequivocally that the adenine residue is involved in 
complex formation; for Zn2+ the situation is less clear from these data. These observations will 
be discussed further below in Section 2.8. 
From the values listed in column 6 of Table 7, which follow from the differences of the 
log DM/NP values of the complexes formed with HPMPA2– and PMEA2–, one may estimate the 
effect of the hydroxyl group of the HO–CH2– side chain (Figure 1). All the differences are very 
small, that is, they are mostly zero within the error limits. There is possibly a small positive 
difference for the D log DHPMPA–PMEA values in the case of the Ni2+ and Cu2+ complexes, but the 
values are so small that they do not justify to postulate the involvement of the hydroxyl group of 
HPMPA2–, especially as there is no sign for such an interaction in the Ni2+ and Cu2+ complexes 
of HPMP2– as comparisons with the corresponding PME2– complexes show (Table 7, column 
7).[47] Consequently, we conclude that in all M(HPMPA) complexes the hydroxyl group does not 
participate in a significant manner in complex formation. Hence, in all instances, with the clear 
exception of Ni2+ and Cu2+ (and possibly Zn2+), for which the adenine residue participates (see 
below in Section 2.8), there are only two isomeric complexes to be considered. That is, an open 
(op) species with a phosphonate coordination alone and a closed (cl) species involving the ether 
oxygen, i.e., Equilibrium (19) is of relevance. The formation degrees of these 5-membered 
chelates are already listed in column 6 of Table 6; they vary between about 20 and 70% 
demonstrating their importance. 
 
2.8 Intramolecular Equilibria in the M(HPMPA) Complexes of Ni2+, Cu2+, and Zn2+ 
 
As discussed before, for the HPMPA2– complexes of Ni2+, Cu2+, and possibly Zn2+ the complete 
upper pathway of the Equilibrium Scheme (12) is of relevance. This means, we have to deal with 
three isomeric species: (i) an open (op) isomer with a metal ion-phosphonate coordination only, 
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M(HPMPA)op, (ii) a closed (cl) species, M(HPMPA)cl/O, involving the ether-oxygen in a 5-
membered chelate as seen in Equilibrium (19), and (iii) a tridentate chelate in which the 5- and a 
7-membered ring is formed, the 7-membered one involving N3, M(HPMPA)cl/O/N3 (see Figure 4 
and also the ligand structure in Figure 1). 
insert Figure 4 close to here 
Analogous schemes involving three different isomers have been evaluated before;[38,47,85] 
therefore we will keep the following elaboration brief. The experimentally accessible stability 
constant [Eq. (5)] refers to the sum of all isomeric M(HPMPA) complexes [Eq. (16)] as 
discussed before in the context of the upper part of Equilibrium Scheme (12). Hence, Equations 
(13) through (18) can be applied. The corresponding results are summarized in Table 8. 
insert Table 8 close to here 
From the results in Table 8 it follows that all three isomers seen in the upper pathway of 
the Equilibrium Scheme (12) are of relevance, but it is also clear that in the three M2+/HPMPA2– 
systems, that is, with M2+ = Ni2+, Cu2+, and Zn2+, the M(HPMPA)cl/O/N3 species are in fact the 
dominating isomers. Note that this indicates that under special conditions N3 can be an 
important metal ion binding site (see also Section 3). 
 
3. Conclusions 
 
Both HPMPA and PMEA are active antivirals,[88] albeit with different activity spectra. Whilst 
HPMPA can be considered as a broad-spectrum antiviral compound against DNA viruses, 
PMEA has only low activity against these. In turn, PMEA is active against retroviruses, whereas 
HPMPA is not.[89] Both compounds are active against herpes and pox viruses. HPMPA tends to 
be a better substrate for kinases than PMEA,[90] and its diphosphoryl derivative can act as 
alternative substrate for DNA polymerases,[17] a feat that is not possible for PMEApp.[20] The 
latter mechanistic differences are owed to the hydroxymethyl group present in HPMPA that 
renders it a closer structural analogue of dAMP. 
However, in terms of ligand basicity (Table 1) and metal complex formation (Tables 2 and 
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7), the hydroxyl group in HPMPA does not affect the stability of protonated or metallated 
species; therefore the speciation of metal complexes with HPMPA2– is closely similar to that of 
PMEA2–.[38] Both ligands form five-membered chelates to a significant extent [e.g., 31% for 
Mg(PMEA) and 24% for Mg(HPMPA)], which may impact substrate recognition by cellular 
enzymes.  
As we have seen, N3 can be an important binding site, a fact that has been long overlooked 
because its basicity has been underestimated. It has recently been shown that N3 of adenosine 
possesses remarkable basic properties: The micro acidity constant pk(N3)H of monoprotonated 
adenosine is 1.5 ± 0.3,[27] and in accord herewith the acyclic adenine-containing nucleotide 
analogues PMEA2– and HPMPA2– show the potential of (N3)-metal ion coordination. This is a 
fundamentally important observation, if one recalls that N3 is exposed to the solvent in the minor 
groove of DNA.[25] 
The significant tendency of HPMPA, and by inference, its congeners including Tenofovir 
(= PMPA; see Introduction and Figure 1), to form complexes with essential metal ions including 
Mg2+ and Ca2+ warrants considering whether the formation of such complexes may play any role 
in the pharmacokinetics of acyclic nucleoside phosphonates (ANPs) beyond the direct 
interaction of the metal complexes with the respective enzymes, or indeed in the development of 
any observed side effects of these compounds. Notably, Antiretroviral Therapy seems to be an 
independent risk factor for developing osteoporosis, a consequence of disturbed calcium 
metabolism.[91] The exact causes and consequences for this well-documented association have 
remained unclear. More specifically, treatment with Tenofovir disoproxil has been associated 
with secondary hyperparathyroidism, a condition that can be a consequence of disturbed calcium 
metabolism, and in turn may lead to reduced bone mineral density and osteoporosis.[91] Although 
it can be estimated from pharmacokinetic data[92] that circulating levels of ANPs will not exceed 
tens of micromolar and thus will be outstripped by circulating calcium[93] by two to three orders 
of magnitude, the potential interactions of ANPs with, e.g., plasma calcium and their 
significance has never been investigated directly. Given that small molecules such as clioquinol 
and PBT2 (a second-generation 8-hydroxyquinoline analog) seem to profoundly affect zinc and 
copper distribution in brain despite their modest affinities,[94] it may be worth considering similar 
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mechanisms for phosphonates adversely affecting whole-body calcium distribution in patients. 
 
4. Experimental Section 
 
The free acid of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine, i.e., H2(HPMPA)± 
(Figure 1), was prepared as described.[41,95,96] The same lot had been used previously for the 
studies of the ternary Cu(Arm)(HPMPA) complexes,[39] where Arm = 2,2'-bipyridine or 1,10-
phenanthroline. All the other reagents were the same as used before in related studies.[37,47] The 
ionic strength, I, was always adjusted at 25°C to 0.1 M with NaNO3 (when needed). 
The experiments with HPMPA were carried out exactly like those described for 
HPMPC,[47] that is, the experimental procedures, the concentrations, and the equipment used, as 
well as the calculation procedures, etc., employed. 
However, a few points warrant emphasis: 
(i) Because the applied pH scale is based on proton activity, the acidity constants determined are 
so-called practical, mixed, or Brønsted constants.[59,60] The negative logarithms of these 
constants given for aqueous solution (25°C; I = 0.1 M, NaNO3) can be converted into the 
corresponding concentration constants by subtracting 0.02 from the pKa values listed.[60] The 
measured stability constants of the metal ion complexes are, as usually, concentration constants. 
(ii) The ligand concentration in the experiments was typically 0.3 mM and the M2+:HPMPA 
ratios were for most metal ions 111:1 and 55.5:1 (see [47]). Due to solubility problems the 
Zn2+:HPMPA ratios were only 28:1 and 14:1, and those for Cu2+:HPMPA were 11.1:1 and 5.6:1. 
The calculated stability constants of the metal ion complexes showed no dependence on pH or 
on the excess of M2+. 
(iii) The final results given are in each case always the averages of at least seven independent 
pairs of titrations. One titration of such a pair was without ligand and this allowed to define the 
beginning of the hydrolysis of M(aq)2+ (= hydroxo complex formation); at this point data 
collection for the calculation of the stability constant of a complex was stopped. 
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Table 1.  Negative logarithms of the acidity constants [Equations (1) to (3)] for aqueous solutions of H3(HPMPA)+ (Figure 1), together with corresponding  
data of related systems for comparison (25 °C; I = 0.1 M, NaNO3)[a,b] 
 
No. 
 
Protonated Species 
pKa for the site  
Refs P(O)(OH)2  (N7)H+ (N1)H+ P(O) (OH) 
 1 H(9MeA)+  (2.96 ± 0.10)[f] 4.10 ± 0.01  [53] 
 2 H2(HPMP) 1.51 ± 0.06[c]   6.94 ± 0.01 [47] 
 3 H3(HPMPA)+ 1.16 ± 0.10[c]  4.14 ± 0.01[h] 6.84 ± 0.01[h] [49] 
 4 H2(PME) 1.57 ± 0.15[d]   7.02 ± 0.01 [38,54] 
 5 H3(PMEA)+ 1.22 ± 0.13[c]  4.16 ± 0.02 6.90 ± 0.01 [38,43] 
 6 H(Ado)+  (2.15 ± 0.15)[g] 3.61 ± 0.03  [23,27] 
 7 H2(RibMP) 0.81 ± 0.06[c]   6.24 ± 0.01 [55] 
 8 H3(AMP)+ 0.4   ± 0.2[e]  3.84 ± 0.02 6.21 ± 0.01 [56,57] 
 9 CH3OP(O)(OH)2 1.1   ± 0.2   6.36 ± 0.01 [58] 
10 CH3P(O)(OH)2 2.10 ± 0.03   7.51 ± 0.01[i] [58] 
[a]  So-called practical, mixed or Brønsted constants, determined (mostly) by potentiometric pH titrations, are listed (see also 4. Experimental Section).[59,60] 
[b]  The error limits given are three times the standard error of the mean value (3s) or the sum of the probable systematic errors, whichever is larger. The error 
limits of the derived data, in the present case partly in column three (estimates based on differences),[c] were calculated according to the error propagation after 
Gauss. 
[c]  Estimate based on the information given in ref.[43] 
[d]  Estimate;[61] see also ref.[43] 
[e]  Determined by 1H NMR shift experiments.[23] 
[f]  This micro acidity constant reflects the basicity of N7 under conditions where N1 does not carry a proton; i.e.,  = 2.96 ± 0.10 holds for the species 
+H·N7(9MeA)N1. For the macro acidity constant  = –0.64 ± 0.06 holds as measured by UV spectrophotometry.[53,62] 
[g]  Micro acidity constant reflecting the basicity of N7 (cf. [f]), i.e.,  = 2.15 ± 0.15 [27] holds for the species +H·N7(Ado)N1. The macro acidity 
constant of H2(Ado)2+ is  = –1.50 ± 0.15.[53] Note, a change of I from 0.1 to 0.5 M has no remarkable effect on the value.[27] 
[h]  These values[49] were confirmed by potentiometric pH titrations in the present study. By 1H NMR shift measurements in D2O and transformation of the results 
to H2O as solvent[63] the following results were obtained: pKa = 6.86 ± 0.11 [for P(O) (OH)], 4.23 ± 0.08 [for (N1)H+] and 1.27 ± 0.11 [for P(O)(OH)2].[64] 
[i]  In ref.[38] pKa = 7.53 ± 0.01 is given.
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Table 2. Logarithms of the stability constants of the M(H;HPMPA)+ [Equation (4)] and 
M(HPMPA) complexes [Equation (5)], together with the negative logarithms of the acidity 
constants of the protonated M(H;HPMPA)+ species [Equations (6), (7)] as determined by 
potentiometric pH titrations (aq. sol.; 25°C; I = 0.1 M, NaNO3)[a] 
M2+ log  log   
Ba2+ 0.0   ± 0.5[b] 1.33 ± 0.03 5.5   ± 0.5 
Sr2+ 0.0   ± 0.3 1.39 ± 0.04 5.45 ± 0.3 
Ca2+ 0.1   ± 0.3 1.64 ± 0.03 5.3   ± 0.3 
Mg2+ 0.1   ± 0.3 1.81 ± 0.03 5.1   ± 0.3 
Mn2+ 0.6   ± 0.2 2.46 ± 0.02 4.98 ± 0.2 
Co2+ 0.84 ± 0.11 2.37 ± 0.02 5.31 ± 0.11 
Ni2+ 1.28 ± 0.10 2.55 ± 0.02 5.57 ± 0.10 
Cu2+ 1.79 ± 0.22[c] 4.05 ± 0.04[c] 4.58 ± 0.22[c] 
Zn2+ 1.43 ± 0.18[c] 2.85 ± 0.15[c,d] 5.42 ± 0.23[c] 
Cd2+ 1.25 ± 0.05 3.01 ± 0.04 5.08 ± 0.06 
[a]  For the acidity constants of the protonated ligand, H3(HPMPA)+, see Table 1. For the error 
limits see footnote [b] of Table 1. 
[b]  Estimate; the formation degree of Ba(H;HPMPA)+ was very low. 
[c]  Constants determined previously[49] are log  = 1.73 ± 0.12, log   = 
4.04 ± 0.03, and   = 4.53 ± 0.12, as well as log  = 1.2 ± 0.2, log 
 = 2.73 ± 0.10, and  = 5.3 ± 0.2. 
[d]  Experiment hampered by precipitation; i.e., the pH range accessible to evaluation was 
restricted. 
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Table 3. Estimation of the micro stability constant of the (H·HPMPA·M)+ isomer (upper 
pathway in the scheme of Figure 2) in aqueous solution at 25°C and I = 0.1 to 0.5 M[a] 
M2+ mav[b] log 
[c] mav·D pKa[d] log [e] [f] 
Mn2+ 0.117 ± 0.065 0.04 ± 0.09 0.062 ± 0.035 0.50 ± 0.18 3.16 ±   1.31 
Co2+ 0.126 ± 0.060 0.23 ± 0.05 0.067 ± 0.032 0.70 ± 0.16 5.01 ±   1.85 
Ni2+ 0.158 ± 0.043 0.40 ± 0.05 0.084 ± 0.023 0.88 ± 0.16 7.59 ±   2.80 
Cu2+ 0.394 ± 0.003 0.84 ± 0.04 0.209 ± 0.012 1.45 ± 0.16 28.18 ± 10.38 
Zn2+ 0.194 ± 0.091 0.15 ± 0.04 0.103 ± 0.049 0.65 ± 0.16 4.47 ±   1.65 
Cd2+ 0.212 ± 0.081 0.64 ± 0.03 0.112 ± 0.043 1.15 ± 0.16 14.13 ±   5.20 
[a]  For the error limits see footnote [b] of Table 1. 
[b]  Average of the slopes m of the straight lines obtained for log K versus pKa plots for o-
substituted pyridine-type ligands[77] as well as for benzimidazole-type ligands;[78] see also 
text in Section 2.4. The error limits are chosen such that the slopes m of the two straight 
lines for a given M2+ are covered. 
[c]  Log stability constant of M(Ado)2+ complexes as determined by potentiometric pH titrations 
in aqueous solution at 25°C and I = 0.5 M (NaNO3). Details to be published by L. E. 
Kapinos and H. Sigel; the same values are also given in refs.[81,82] 
[d]  See Equation (9). 
[e]  The logarithms of the micro stability constants (see Figure 2; upper part at the left) are 
calculated according to Equation (9). The first two terms of this equation are given above in 
columns 3 and 4. The charge effect of 0.40 ± 0.15 log units[38,56,59,80] reflects the effect of the 
difference in charge between M(Ado)2+ and (H·HPMPA·M)+, that is, in the first case the 
reaction takes place (see also text in Section 2.4) between M2+ and the neutral Ado whereas 
in the second case the reaction occurs with (H·HPMPA)– (see structures in Figure 1). This 
value due to the charge effect is added to the sum of the two values given at the left in 
columns 3 and 4. 
[f]  These micro stability constants, which follow from the log values at the left, are needed for 
the evaluations summarized in Table 5.
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Table 4. Summary of the microconstants defined in the equilibrium scheme of Figure 2[a] 
M2+  
– log [b] 
log [c] log [d] [e] [f] 
Mn2+ 4.38 ± 0.02 0.50 ± 0.18 –0.09 ± 1.20[f] 4.88 ± 0.18 4.29 ± 1.20 
Co2+ 4.47 ± 0.02 0.70 ± 0.16 0.28 ± 0.58[f] 5.17 ± 0.16 4.75 ± 0.58 
Ni2+ 4.29 ± 0.02 0.88 ± 0.16 1.06 ± 0.20 5.17 ± 0.16 5.35 ± 0.20 
Cu2+ 2.79 ± 0.04 1.45 ± 0.16 1.52 ± 0.43 4.24 ± 0.16 4.31 ± 0.43 
Zn2+ 3.99 ± 0.15 0.65 ± 0.16 1.35 ± 0.22 4.64 ± 0.22 5.34 ± 0.27 
Cd2+ 3.83 ± 0.04 1.15 ± 0.16 0.56 ± 0.66[f] 4.98 ± 0.16 4.39 ± 0.66 
[a]  For the error limits see footnote [b] of Table 1. 
[b]  The relevant acidity constant is  = 6.84 ± 0.01 (Table 1; entry 3, column 6) and the values for log  are listed  
in column 3 of Table 2; hence, the values in the above column 2 can be calculated. 
[c]  These micro stability constants (see at the left in the upper part of the equilibrium scheme in Figure 2) are from column 5 in Table 3. 
[d]  These micro stability constants are calculated with Equation (a) given in the lower part of Figure 2, by applying the log stability constants,  
log , of column 2 in Table 2 and the log of the micro stability constants in column 5 of Table 3. 
[e]  These values follow from the closed circle in the upper pathway of the equilibrium scheme; the same is true for the lower pathway [see also 
Equation (c)]. 
[f]  The error limits are so large because the difference is taken between two very similar values in the closed circle, e.g., in the case of Mn2+ 
between  = 3.98 ± 1.83 and  = 3.16 ± 1.31, which amounts to  = 0.82 ± 2.25 (and also to log 
  = –0.09 ± 1.20 as given in column 4).
 
pKH(HPMPA)
H
 
KM(HPMPA)
M  kH⋅HPMPA⋅M
M
 
kH(M⋅HPMPA)
M
 pkH⋅HPMPA⋅M
H
 
pkH(M⋅HPMPA)
H
 
pKH(HPMPA)
H
 
KM(HPMPA)
M
 
KM(H;HPMPA)
M
 
KM(H;HPMPA)
M
 kH⋅HPMPA⋅M
M
 
kH(M⋅HPMPA)
M
 
kH(Mn⋅HPMPA)
Mn
  
32 
Table 5. Isomeric distribution and formation degree of the (H·HPMPA·M)+ species with M2+ at 
the nucleobase residue (aq. sol.; 25°C; I = 0.1 M)[a] 
M2+ [b] [c] [d]     R[e] % (H·HPMPA·M)+[f] 
Mn2+ 3.98 ±   1.83 3.16 ±   1.31 0.82 ±   2.25 3.85 79 (ca. 100; 47) 
Co2+ 6.92 ±   1.75 5.01 ±   1.85 1.91 ±   2.55 2.62 72 (99; 46) 
Ni2+ 19.05 ±   4.39 7.59 ±   2.80 11.46 ±   5.21 0.66 40 (55; 25) 
Cu2+ 61.66 ± 31.24 28.18 ± 10.38 33.48 ± 32.92 0.84 46 (63; 29) 
Zn2+ 26.92 ± 11.16 4.47 ±   1.65 22.45 ± 11.28 0.20 17 (23; 11) 
Cd2+ 17.78 ±   2.05 14.13 ±  5.20 3.65 ±   5.59 3.87 79 (ca 100; 50) 
[a]  For the error limits see footnote [b] of Table 1. 
[b]  These values follow from those given in column 2 of Table 2. 
[c]  These values are from the terminating column in Table 3. 
[d]  Calculated according to Equation (a) in Figure 2. 
[e]  See Equation (10).  
[f]  See Equation (11). The values in parentheses refer to the upper and lower limits, 
respectively, for % (H·HPMPA·M)+ as they result from the use of the upper and lower limits 
for  (above in column 3). The difference to 100% describes the formation degree 
of the H(M·HPMPA)+ species. 
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Table 6. Stability constant comparisons according to Equation (17) for the M(HPMPA) 
complexes between the experimentally measured (exp) and the calculated (calc) log stability 
constants, together with the resulting intramolecular equilibrium constants, KI/tot [Equation 
(18)], and the formation degrees of the total amount of chelated species, M(HPMPA)cl/tot (aq. 
sol.; 25°C; I = 0.1 M, NaNO3)[a] 
M2+ 
  log  
   log DM/HPMPA[d]  KI/tot[e] %(HPMPA)cl/tot[f] 
  exp[b]     calc[c] 
Ba2+ 1.33 ± 0.03 1.22 ± 0.04 0.11 ± 0.05 0.29 ± 0.15 22 ±   9 
Sr2+ 1.39 ± 0.04 1.29 ± 0.04 0.10 ± 0.06 0.26 ± 0.16 21 ± 10 
Ca2+ 1.64 ± 0.03 1.53 ± 0.05 0.11 ± 0.06 0.29 ± 0.17 22 ± 10 
Mg2+ 1.81 ± 0.03 1.69 ± 0.03 0.12 ± 0.04 0.32 ± 0.13 24 ±   7 
Mn2+ 2.46 ± 0.02 2.31 ± 0.05 0.15 ± 0.05 0.41 ± 0.18 29 ±   9 
Co2+ 2.37 ± 0.02 2.08 ± 0.06 0.29 ± 0.06 0.95 ± 0.28 49 ±   7 
Ni2+ 2.55 ± 0.02 2.10 ± 0.05 0.45± 0.05 1.82 ± 0.35 65 ±   4 
Cu2+ 4.05 ± 0.04 3.17 ± 0.06 0.88 ± 0.07 6.59 ± 1.26 87 ±   2 
Zn2+ 2.85 ± 0.15 2.34 ± 0.06 0.51 ± 0.16 2.24 ± 1.20 69 ± 11 
Cd2+ 3.01 ± 0.04 2.65 ± 0.05 0.36 ± 0.06 1.29 ± 0.34 56 ±   6 
[a]  For the error limits see footnote [b] of Table 1. 
[b]  From column 3 in Table 2. 
[c]  Calculated with the previously established parameters[35,38,66,73] for the reference-line 
equations [Eq. (20)] and  = 6.84 ± 0.01 (Table 1, entry 3). 
[d]  See Equation (17). 
[e]  See Equation (18). 
[f]  See Equation (21).
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Table 7. Comparison of the log DM/NP values, which quantify according to Equation (17) any stability enhancement due to chelate formation for 
the complexes formed with HPMPA2–, HPMP2–, and PMEA2–, allowing thus conclusions regarding the influence of the adenine residue and the 
hydroxyl group (aq. sol.; 25°C; I = 0.1 M, NaNO3)[a] 
M2+ log DHPMPA log DHPMP D log DHPMPA–HPMP log DPMEA D log DHPMPA–PMEA D log DHPMP–PME[b] 
Ba2+ 0.11 ± 0.05 0.26 ± 0.04 –0.15 ± 0.06 0.08 ± 0.06 0.03 ± 0.08 0.16 ± 0.06 
Sr2+ 0.10 ± 0.06 0.22 ± 0.05 –0.12 ± 0.08 0.07 ± 0.05 0.03 ± 0.08 0.15 ± 0.07 
Ca2+ 0.11 ± 0.06 0.31 ± 0.05 –0.20 ± 0.08 0.11 ± 0.07 0.00 ± 0.09 0.17 ± 0.07 
Mg2+ 0.12 ± 0.04 0.21 ± 0.03 –0.09 ± 0.05 0.16 ± 0.05 –0.04 ± 0.06 –0.01 ± 0.04 
Mn2+ 0.15 ± 0.05 0.28 ± 0.05 –0.13 ± 0.07 0.21 ± 0.08 –0.06 ± 0.09 0.01 ± 0.07 
Co2+ 0.29 ± 0.06 0.33 ± 0.06 –0.04 ± 0.08 0.28 ± 0.07 0.01 ± 0.09 0.04 ± 0.08 
Ni2+ 0.45 ± 0.05 0.25 ± 0.05 0.20 ± 0.07 0.30 ± 0.07 0.15 ± 0.08 0.06 ± 0.07 
Cu2+ 0.88 ± 0.07 0.54 ± 0.07 0.34 ± 0.10 0.77 ± 0.07 0.11 ± 0.10 0.06 ± 0.10 
Zn2+ 0.51 ± 0.16 0.43 ± 0.06 0.08 ± 0.17 0.30 ± 0.10 0.21 ± 0.19 0.09 ± 0.08 
Cd2+ 0.36 ± 0.06 0.33 ± 0.05 0.03 ± 0.08 0.33 ± 0.06 0.03 ± 0.08 0.03 ± 0.07 
[a]  For the error limits see footnote [b] of Table 1. The values in the second column are from column 4 in Table 6, those in the 3rd and 5th column 
are from ref.[47] and refs[34,38], respectively. In addition, for example, log DHPMPA should correctly be written as log DM/HPMPA [see also Equation 
(17)], however, for reasons of clarity "M" is deleted in all expressions above. 
[b]  These values are from column 6 in Table 2 of ref.[47].
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Table 8. Total stability enhancements, log DM/HPMPA [Equation (17)], observed for the M(HPMPA) complexes together with the intramolecular 
equilibrium constants and the percentages of the three isomeric species [Equilibrium (12); upper part] involved in the M(HPMPA) complexes of 
Ni2+, Cu2+, and Zn2+ (aq. sol.; 25°C; I = 0.1 M, NaNO3)[a] 
M2+ log 
DM/HPMPA[b] 
KI/tot % 
M(HPMPA)cl/tot[c] 
% 
M(HPMPA)op[d] 
    KI/O[e] 
 
     KI/O/N3[f] % 
M(HPMPA)cl/O[c] 
% 
M(HPMPA)cl/O/N3[g] 
Ni2+ 0.45 ± 0.05 1.82 ± 0.33 65 ±   4 35 ±   4 0.38 ± 0.22 3.79 ± 2.91 13 ±   8 52 ±   9 
Cu2+ 0.88 ± 0.07 6.59 ± 1.22 87 ±   2 13 ±   2 2.02 ± 0.49 2.26 ± 1.00 26 ±   8 61 ±   9 
Zn2+ 0.51 ± 0.16 2.24 ± 1.19 69 ± 11 31 ± 11 0.95 ± 0.31 1.36 ± 1.47 29 ± 14 40 ± 18 
[a]  For the error limits see footnote [b] of Table 1. 
[b]  Values taken from column 4 in Table 6. The use of these log DM/HPMPA values for the calculation of KI/tot [Equation (18)] provides the same KI/tot 
values, but slightly different error limits than those given in Table 6 (column 5), which are based on log Kexp and log Kcalc. Note, this has no 
effect on the values (including the error limits) calculated for % M(HPMPA)cl/tot. 
[c]  Analogous to Equation (21). 
[d]  % M(HPMPA)op = 100% – % M(HPMPA)cl [Equation (22)].  
[e]  These values are from Table 6 (column 3) of ref.[44]; they refer to systems in which only the 5-membered chelate can form. 
[f]  Calculated with Equation (18). 
[g]  These values follow from % M(HPMPA)cl/O/N3 = % M(HPMPA)cl/tot – % M(HPMPA)cl/O. They can also be calculated analogous to Equation 
(21), but then the errors are understandably larger.
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Legends for the Figures 
 
Figure 1. Chemical structures of acyclic nucleoside phosphonates, that is, of the dianions of 9-[2-
(phosphonomethoxy)ethyl]adenine (PMEA2–) and (S)-9-[3-hydroxy-2-
(phosphonomethoxy)propyl]adenine (HPMPA2–) together with the structures of the nucleobase-
free derivatives (phosphonomethoxy)ethane (PME2– = (ethoxymethyl)phosphonate) and (R)-
hydroxy-2-(phosphonomethoxy)propane (HPMP2–). It is assumed that the orientation of 
HPMPA2– corresponds to the one observed for PMEA2– in solution[21] and in the solid state,[22] 
which resembles the anti conformation of the parent nucleotide, that is, adenosine 5'-
monophosphate (AMP2–).[23–26] AMP2–, as well as the structures of 9-methyladenine (9MeA) and 
adenosine (Ado; also shown in its dominating anti conformation[27]) are given for comparison. 
(R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA; Tenofovir) lacks the 3-hydroxyl group 
present in HPMPA. All charged five compounds in the figure are also abbreviated as NP2– = 
nucleoside phosph(on)ate derivative. 
 
Figure 2. Equilibrium scheme for the reaction M2+ + H(HPMPA)– to M(HPMPA) + H+ which is 
shown in the upper part of the figure for Ni2+ as an example. In the lower part the interrelations 
between the macro- and microconstants are given in a general manner for M2+ [Eqs (a), (b), and 
(c)]. The equilibrium scheme shows the interrelation for the monoprotonated isomers of 
Ni(H;HPMPA)+, written as (H·HPMPA·Ni)+, with the metal ion at the adenine residue and the 
proton at the phosphonate group (upper pathway) and H(Ni·HPMPA)+ with both Ni+ and H+ at 
the phosphonate group (lower pathway; see text in Section 2.4). Also shown are the other species 
in equilibrium with (H·HPMPA·Ni)+ and H(Ni·HPMPA)+. The arrows indicate the directions for 
which the constants are defined. The macroconstants are from Tables 1 and 2; the 
microconstants were derived by applying Equations (a), (b), and (c), together with the 
assumptions described in the text (Table 3). Further evaluations (Table 4) provide finally the 
ratio R and the percentages of the isomers of the monoprotonated complexes (Table 5). 
 
Figure 3. Evidence for an enhanced stability of some M(HPMPA) () complexes in comparison 
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with those of the corresponding M(PMEA) (U), M(HPMP) (¿), and M(PME) (r) species [all 
abbreviated as M(NP)], based on the relationship between log and  for 
M(R-PO3) complexes () of some simple phosphate monoester and phosphonate ligands  
(R-PO ): 4-nitrophenyl phosphate (NPhP2– ), phenyl phosphate (PhP2–), uridine 5'-
monophosphate (UMP2–), D-ribose 5-monophosphate (RibMP2–), thymidine [= 1-(2'-deoxy-b-D-
ribofuranosyl)thymine] 5'-monophosphate (dTMP2–), n-butyl phosphate (BuP2–), 
methanephosphonate (MeP2–), and ethanephosphonate (EtP2–) (from left to right). The least-
squares lines [Equation (20)][38,66,73] are drawn through the corresponding 8 data sets () taken 
from ref.[55] for the phosphate monoesters and from ref.[38] for the phosphonates. The points due 
to the equilibrium constants for the M2+/HPMPA () systems are based on the values listed in 
Tables 1 and 2; those for the M2+/PMEA systems (U) are from ref.[38], for the M2+/HPMP 
systems (¿) from ref.[47], and those for the M2+/PME systems (r) from ref.[38]. The vertical 
(broken) lines emphasize the stability differences based on the reference lines; they equal log 
DM/NP as defined in Equation (17), for the M(NP) complexes in general. All the plotted 
equilibrium constants refer to aqueous solutions at 25°C and I = 0.1 M (NaNO3). 
 
Figure 4. Possible structure of a tridentate chelate with Cu2+ as central ion in a square planar 
geometry, involving the phosphonate group, the ether oxygen, and N3 of the adenine ring. 
Carbon atoms are shown in grey, nitrogen in blue, oxygens in red, phosphorus in magenta, and 
copper in cyan. Potential axial water ligands and all hydrogen atoms are omitted for clarity. The 
model was generated in Chem3D Pro v. 17, with customized restraints for distances, angles, and 
dihedral angles, some of which were extracted from the Cambridge Structural Database. 
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The primary binding site is the phosphonate group which forms with the ether O a  
5-membered chelate, M(HPMPA)cl/O. With varying formation degrees this intramolecular 
equilibrium holds for all metal ions studied. However, with Ni2+, Cu2+, and Zn2+ a further 
interaction is possible, that is, with N3 a 7-membered chelate is formed, M(HPMPA)cl/O/N3.  
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The primary binding site is the phosphonate group which forms with the ether O a  
5-membered chelate, M(HPMPA)cl/O. With varying formation degrees this intramolecular 
equilibrium holds for all metal ions studied. However, with Ni2+, Cu2+, and Zn2+ a further 
interaction is possible, that is, with N3 a 7-membered chelate is formed, M(HPMPA)cl/O/N3. 
 
